Merck agrees on the importance of making our medicines available to those who need them. That is why we implemented a clear, straightforward HIV pricing policy more than four years ago. Under this policy, Merck makes no profit on the sale of our medicines CRIXIVAN (indinavir sulfate) and STOCRIN (efavirenz) in the world’s poorest countries and those hardest hit by the AIDS pandemic. This includes all low HDI countries, as determined by the United Nations Development Program’s Human Development Index, as well as all medium HDI countries with an adult HIV prevalence rate of 1 percent or greater, as reported by UNAIDS...Merck welcomes the availability of generic medicines in markets where patents have expired or do not exist. [also refers to Cipla, Ranbaxy]